Abstract
I was intrigued to see the recent trial of Liu et al1reporting the benefits of exenatide over metformin in terms of weight loss and pregnancy rate in women with polycystic ovary syndrome. I am writing to clarify the discrepancies between the trial as registered and the trial as reported in the manuscript. According to the trial registration on the Chinese Clinical Trial Registration Site (ChiCTR-IIR-16008084) the trial was a three armed trial for exenatide, metformin, or spironolactone.
This article is protected by copyright. All rights reserved.
http://ift.tt/2h0jF5f
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου